XTRA:FME

Stock Analysis Report

Fresenius Medical Care KGaA

Executive Summary

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally.

Snowflake

Fundamentals

Established dividend payer and fair value.


Similar Companies

Share Price & News

How has Fresenius Medical Care KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.2%

XTRA:FME

1.6%

DE Healthcare

1.8%

DE Market


1 Year Return

-29.7%

XTRA:FME

-25.8%

DE Healthcare

-3.5%

DE Market

FME underperformed the Healthcare industry which returned -25.8% over the past year.

FME underperformed the Market in Germany which returned -3.5% over the past year.


Share holder returns

FMEIndustryMarket
7 Day1.2%1.6%1.8%
30 Day6.1%6.3%7.2%
90 Day-6.6%-4.0%3.5%
1 Year-28.6%-29.7%-24.5%-25.8%-0.5%-3.5%
3 Year-15.7%-19.0%-24.9%-27.6%20.6%10.3%
5 Year22.7%15.5%22.7%15.8%30.7%12.8%

Price Volatility Vs. Market

How volatile is Fresenius Medical Care KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fresenius Medical Care KGaA undervalued based on future cash flows and its price relative to the stock market?

38%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Fresenius Medical Care KGaA's share price is below the future cash flow value, and at a moderate discount (> 20%).

Fresenius Medical Care KGaA's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Fresenius Medical Care KGaA is good value based on earnings compared to the DE Healthcare industry average.

Fresenius Medical Care KGaA is good value based on earnings compared to the Germany market.


Price Based on Expected Growth

Fresenius Medical Care KGaA is poor value based on expected growth next year.


Price Based on Value of Assets

Fresenius Medical Care KGaA is overvalued based on assets compared to the DE Healthcare industry average.


Next Steps

Future Growth

How is Fresenius Medical Care KGaA expected to perform in the next 1 to 3 years based on estimates from 22 analysts?

12.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Fresenius Medical Care KGaA's revenue is expected to grow by 6.5% yearly, however this is not considered high growth (20% yearly).

Fresenius Medical Care KGaA's earnings are expected to grow by 12.8% yearly, however this is not considered high growth (20% yearly).

Fresenius Medical Care KGaA's revenue growth is expected to exceed the Germany market average.

Fresenius Medical Care KGaA's earnings growth is positive but not above the Germany market average.

Fresenius Medical Care KGaA's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Fresenius Medical Care KGaA is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Fresenius Medical Care KGaA performed over the past 5 years?

17.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Fresenius Medical Care KGaA's year on year earnings growth rate has been positive over the past 5 years.

Fresenius Medical Care KGaA's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Fresenius Medical Care KGaA's 1-year earnings growth is negative, it can't be compared to the DE Healthcare industry average.


Return on Equity

Fresenius Medical Care KGaA has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Fresenius Medical Care KGaA used its assets more efficiently than the DE Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

Fresenius Medical Care KGaA's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Fresenius Medical Care KGaA's financial position?


Financial Position Analysis

Fresenius Medical Care KGaA's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Fresenius Medical Care KGaA's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Fresenius Medical Care KGaA's level of debt (69.7%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (88.6% vs 69.7% today).

Debt is well covered by operating cash flow (26.7%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.9x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are 0.8x debt.


Next Steps

Dividend

What is Fresenius Medical Care KGaA's current dividend yield, its reliability and sustainability?

2.06%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Fresenius Medical Care KGaA's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.4%).

Fresenius Medical Care KGaA's dividend is below the markets top 25% of dividend payers in Germany (3.85%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (3.4x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (4x coverage).


Next Steps

Management

What is the CEO of Fresenius Medical Care KGaA's salary, the management and board of directors tenure and is there insider trading?

6.5yrs

Average management tenure


CEO

Rice Powell (64yo)

6.7yrs

Tenure

€6,625,000

Compensation

Mr. Robert Maurice Powell, Jr., also known as Rice, has been the Chief Executive Officer and Chairman of Management at Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & C ...


CEO Compensation Analysis

Rice's remuneration is higher than average for companies of similar size in Germany.

Rice's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

6.5yrs

Average Tenure

58.5yo

Average Age

The average tenure for the Fresenius Medical Care KGaA management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

1.3yrs

Average Tenure

70yo

Average Age

The average tenure for the Fresenius Medical Care KGaA board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Mike Brosnan (64yo)

    CFO & Member of the Management Board at Fresenius Medical Care Mgmt AG

    • Tenure: 9.7yrs
    • Compensation: €3.94m
  • Rice Powell (64yo)

    Chairman of the Management Board & CEO of Fresenius Medical Care Mgmt AG

    • Tenure: 6.7yrs
    • Compensation: €6.63m
  • Joachim Weith

    Senior Vice President of Corporate Communications & Governmental Affairs

    • Tenure: 0yrs
  • Kent Wanzek (60yo)

    CEO of Global Mfg

    • Tenure: 9.7yrs
    • Compensation: €3.04m
  • Borries Muller (58yo)

    Senior Vice President of Global Human Resources Employee Communications

    • Tenure: 0yrs
  • Harry de Wit (57yo)

    CEO of APAC & Member of Management Board - Fresenius Medical Care Mgmt AG

    • Tenure: 3.4yrs
    • Compensation: €2.66m
  • Olaf Schermeier (47yo)

    CEO of Global R&D and Member of the Management Board - Fresenius Medical Care Mgmt AG

    • Tenure: 6.5yrs
    • Compensation: €2.70m
  • Bill Valle (59yo)

    CEO of North America & Member of Management Board at Fresenius Medical Care Mgmt AG

    • Tenure: 2.7yrs
    • Compensation: €3.83m
  • Dominik Heger

    Executive VP and Head of Investor Relations

    • Tenure: 0yrs
  • Katarzyna Mazur-Hofsäß (56yo)

    CEO for EMEA & Member of Management Board - Fresenius Medical Care Mgmt AG

    • Tenure: 1yrs
    • Compensation: €2.79m

Board Members

  • Ben Lipps (79yo)

    Honorary Chairman of Supervisory Board

    • Tenure: 3.2yrs
  • Rolf Classon (74yo)

    Vice Chairman of Supervisory Board

    • Tenure: 0.8yrs
    • Compensation: €305.00k
  • Dieter Schenk (66yo)

    Chairman of Supervisory Board

    • Tenure: 1.3yrs
    • Compensation: €296.00k
  • William Johnston (74yo)

    Member of Supervisory Board

    • Tenure: 13.3yrs
    • Compensation: €300.00k
  • Gregor Zünd (59yo)

    Member of Supervisory Board

    • Tenure: 0.9yrs
    • Compensation: €25.00k
  • Pascale Witz (52yo)

    Member of Supervisory Board

    • Tenure: 3.3yrs
    • Compensation: €143.00k
  • Dorothea Wenzel

    Member of Supervisory Board

    • Tenure: 0.3yrs

Company Information

Fresenius Medical Care AG & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fresenius Medical Care AG & Co. KGaA
  • Ticker: FME
  • Exchange: XTRA
  • Founded: 1996
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: €19.205b
  • Shares outstanding: 304.83m
  • Website: https://www.freseniusmedicalcare.com

Number of Employees


Location

  • Fresenius Medical Care AG & Co. KGaA
  • Else-Kröner Strasse 1
  • Bad Homburg
  • Hessen
  • 61352
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FMSNYSE (New York Stock Exchange)ADR-EACH REP 0.5 NPVUSUSDSep 1996
FMEADB (Deutsche Boerse AG)ADR-EACH REP 0.5 NPVDEEURSep 1996
FMEDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 1996
FMEDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 1996
0H9XLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 1996
FMEXTRA (XETRA Trading Platform)YesOrdinary SharesDEEUROct 1996
FMCQ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 1996
FMEWBAG (Wiener Boerse AG)YesOrdinary SharesATEUROct 1996
FME NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNOct 1996
FMESWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFOct 1996
FMEBIT (Borsa Italiana)YesOrdinary SharesITEUROct 1996
FRESENIUSBOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH REPR 1 ADRBRBRLSep 2019

Biography

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers di ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 21:13
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.